SCHEMBL18004145

SCHEMBL18004145

N#Cc1[nH]nnc1-c1ccc(-c2ccccc2-c2ccccc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 1/20 0.40
GRM5 P41594 2/20 0.40
ADORA1 P30542 6/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
DCUN1D2 Q6PH85 1/20 0.37
DCUN1D1 Q96GG9 1/20 0.37
CHEK1 O14757 1/20 0.37
ABL1 P00519 1/20 0.37
PDGFRB P09619 1/20 0.37
PDGFRA P16234 1/20 0.37
FLT1 P17948 1/20 0.37
GRK5 P34947 1/20 0.37
KDR P35968 1/20 0.37
MAP2K2 P36507 1/20 0.37
CDK8 P49336 1/20 0.37
GSK3A P49840 1/20 0.37
GSK3B P49841 1/20 0.37
PRKX P51817 1/20 0.37
NEK2 P51955 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18003907 0.92 DCUN1D2 (0.38) ERBB2GRM5ADORA1MEN1KMT2A
SCHEMBL18003968 0.92 ADORA1 (0.45) ERBB2ADORA1MEN1KMT2ACHEK1
SCHEMBL18004136 0.92 ADORA1 (0.45) ERBB2ADORA1MEN1KMT2ACHEK1
SCHEMBL12386160 0.92 ERBB2 (0.46) ERBB2GRM5ADORA1MEN1KMT2A
SCHEMBL18004024 0.89 GRM5 (0.37) ERBB2GRM5ADORA1DCUN1D2DCUN1D1
SCHEMBL18006085 0.86 ADORA1 (0.42) ADORA1DCUN1D1ADORA2ALMNAALDH1A1
SCHEMBL18006088 0.86 CYP2A6 (0.42) ADORA1KMT2AADORA2ALMNAHSD17B10
SCHEMBL18006158 0.86 AR (0.40) DCUN1D1CHEK1ABL1PDGFRBPDGFRA
SCHEMBL18006098 0.84 MCL1 (0.42) MEN1KMT2AMAPK14HSD17B10ALDH1A1
SCHEMBL18006133 0.83 PTGS2 (0.43) ERBB2MEN1KMT2AABL1MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 ERBB2 4040/4885GRM5 1425/4885ADORA1 3010/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 ERBB2 4040/4885GRM5 1425/4885ADORA1 3010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.